Pharmaceutical companies are increasingly experimenting with biomarkers in order to improve results of their clinical trials. Diagnostics companies are ideally suited to help, but pharma tends to shun them and diagnostics companies perceive that when both sides work together, the diagnostics side has less leverage. Here's how diaDexus believes it can retain clout as it works with GSK on a promising new diagnostic and therapeutic target: Lp-PLA2 for cardiovascular disease.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Radiotherapy enhancer JNJ-1900 (NBTXR3) generated a 47% ORR and 78.9% DCR in melanoma patients after multiple prior rounds of treatment. Discussions about development in additional cancers are ongoing with partner J&J.
CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.
With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.
Shortlists of potential winners in all categories of the Citeline Japan Awards 2025 have now been released. Join us at the event in Tokyo on October 21, it’s not too late to book your table!
CSO Jacob Thyssen tells Scrip that the monoclonal antibody which blocks the IL-22RA1 receptor subunit is a very safe and effective option to treat the chronic inflammatory skin disease.
Pfizer and Arvinas have agreed to out-license their PROTAC breast cancer candidate, vepdegestrant, with Arvinas cutting jobs and refocusing on early-stage assets.
With patent expiry for its blockbuster blood cancer drug Jakafi on the horizon, Incyte will need to translate these povorcitinib wins from clinic to market.
